找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Ganoderma and Health; Pharmacology and Cli Zhibin Lin,Baoxue Yang Book 2019 The Editor(s) (if applicable) and The Author(s), under exclusiv

[復制鏈接]
樓主: MOURN
31#
發(fā)表于 2025-3-26 23:14:20 | 只看該作者
32#
發(fā)表于 2025-3-27 02:45:02 | 只看該作者
33#
發(fā)表于 2025-3-27 08:08:54 | 只看該作者
https://doi.org/10.1007/978-3-322-85369-1re. To date, there are no .-related drugs approved by the US Food and Drug Administration (FDA). In this chapter, we will summarize and elucidate recent progress of such effects of . and its ingredients from both the preclinical and clinical points of view.
34#
發(fā)表于 2025-3-27 11:55:24 | 只看該作者
https://doi.org/10.1007/978-3-8349-8226-1high-fat-diet-induced diabetic, isoprenaline (ISO)-induced myocardial hypertrophy, acute ethanol-induced heart toxicity, and transverse aortic constriction (TAC) models. This chapter summarizes putative preventive and therapeutic effects of . on cardiovascular diseases and the potential clinical use of . involved in these effects.
35#
發(fā)表于 2025-3-27 13:39:52 | 只看該作者
Anreizsysteme in der Beschaffunglast via RANKL/RANK pathway and/or its downstream signaling transduction related to ERK, JNK and p38 MAPKs, contributing to inhibition of the level of c-Fos and NFATc1, two key target genes of osteoclast for osteoclastogenesis. However, the comprehensive mechanism remains to be elucidated in the future.
36#
發(fā)表于 2025-3-27 18:58:34 | 只看該作者
Neuropharmacological Effect and Clinical Applications of , (Lingzhi),re. To date, there are no .-related drugs approved by the US Food and Drug Administration (FDA). In this chapter, we will summarize and elucidate recent progress of such effects of . and its ingredients from both the preclinical and clinical points of view.
37#
發(fā)表于 2025-3-27 23:00:42 | 只看該作者
38#
發(fā)表于 2025-3-28 02:32:06 | 只看該作者
Anti-osteoporosis Effect of , (Lingzhi) by Inhibition of Osteoclastogenesis,last via RANKL/RANK pathway and/or its downstream signaling transduction related to ERK, JNK and p38 MAPKs, contributing to inhibition of the level of c-Fos and NFATc1, two key target genes of osteoclast for osteoclastogenesis. However, the comprehensive mechanism remains to be elucidated in the future.
39#
發(fā)表于 2025-3-28 07:43:36 | 只看該作者
40#
發(fā)表于 2025-3-28 14:01:22 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 07:44
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
涞源县| 宜兰市| 葫芦岛市| 洪江市| 灵丘县| 南木林县| 麻阳| 三门峡市| 丽水市| 光山县| 寻甸| 金门县| 客服| 琼结县| 西乌珠穆沁旗| 离岛区| 股票| 浙江省| 贵定县| 武乡县| 沙洋县| 青龙| 曲周县| 衡水市| 长岛县| 黄梅县| 加查县| 河池市| 景洪市| 涿鹿县| 嘉善县| 昌邑市| 乌拉特后旗| 蕲春县| 萍乡市| 聊城市| 吉安市| 双鸭山市| 虞城县| 灵川县| 定陶县|